Close Menu

ASCO

The American Society of Clinical Oncology held its annual meeting June 1-5 in Chicago.
The following are abstracts presented at the meeting focused on pharmacogenomically guided treatment strategies.

Originally published July 17.

A group of researchers led by Oleg Gluz of the West German Study Group, and including employees of Genomic Health, has shared data from the phase III WSG-Plan B trial showing that high-risk recurrence scores obtained by Genomic Health's Oncotype DX test predict high risk as measu

The American Society of Clinical Oncology is in the midst of developing a rapid-learning system that aims to connect physicians’ practices, measure their performance and quality of care, and advance best practices by providing doctors real-time decision support.

The American Society of Clinical Oncology held its annual meeting June 1 - 5 in Chicago. The following are abstracts presented at the meeting focused on the application of molecular diagnostics to cancer prognosis.

NEW YORK (GenomeWeb News) – If genetic tests that predict individual cancer risk are not reimbursed by health insurers, some people who have received referrals for those tests may opt not to take them, according to a new study from Fox Chase Cancer Center.

Data from the study showed that Rosetta's array-based Mets 2 test has 88 percent concordance with clinical presentation and pathology, exceeding the accuracy of the PCR-based version of the test.

The company hopes the positive safety profile of the drug will entice industry partners interested in licensing siRNA delivery systems, Silence's CEO said.

Alnylam partner Tekmira Pharmaceuticals said it views the data as a validation of its drug-delivery technology, which will be used in two new oncology programs it unveiled this week.

Pages